CVS, Aetna executives defend $69 billion deal to skeptical Wall Street

NEW YORK (Reuters) - CVS Health Corp and Aetna Inc top executives on Monday defended their planned merger to Wall Street analysts and investors who questioned the near-term impact on profits of the $69 billion deal to combine the pharmacy and drug benefit manager with the No. 3 U.S. health insurer.

CVS, Aetna executives defend $69 billion deal to skeptical Wall Street
Read More


Bagikan Berita Ini